Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Should Create “Clearly Articulated Pathway” For Patient-Centered Research – Pfizer’s Lewis-Hall

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer CMO Freda Lewis-Hall acknowledged FDA’s current activities to promote patient-centered research, but called on the agency to lead in developing guidance to help industry be more proactive in incorporating patients into its research.

You may also be interested in...



COPD Patient-Reported Outcome Questionnaire Is Early Example of FDA Drug Development Tool “Approval” Process

FDA finalizes the "qualification process for drug development tools." The topic won't get as much attention as Breakthrough Therapy or Accelerated Approval, but the head of the drug center thinks this is a very big deal. A COPD outcomes assessment is an early example of the process in action.

Can Social Media Help Validate Patient-Reported Outcomes? FDA Reviewer Gives “Resounding Yes”

Work needs to be done to allow for the use of social media to support content validity of patient-reported outcomes, but one FDA endpoints reviewer says there is a place for social media to work alongside traditional methods of validating PROs.

Drug Development Needs “Clean-Slate Think” To Involve Patients All Along The Way – Pfizer’s Lewis-Hall

Drug companies and other stakeholders should collaborate on developing a “clear framework” for patient engagement, Freda Lewis-Hall says at ISPOR.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS076922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel